<DOC>
	<DOCNO>NCT02393560</DOCNO>
	<brief_summary>The purpose study determine presence volume monosodium urate ( MSU ) crystal deposit determine dual-energy compute tomography ( DECT ) image gout subject treat allopurinol without visible tophus .</brief_summary>
	<brief_title>DECT Study Allopurinol-Treated Gout Patients</brief_title>
	<detailed_description>DECT technique enable visualization MSU crystal deposit analysis chemical composition scan material . This study determine extent MSU crystal volume hands/wrists , feet/ankles , knee determine DECT subject gout take dose least 300 mg allopurinol daily past 12 week . Patients gout allopurinol without tophus assess use DECT image crystal deposition assessment , include patient provider assessment disease severity pain , prior scan .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Subject able understand study procedure , risk involve willing provide write informed consent first study related activity . Subject willing adhere visit/protocol schedule . Subject meet diagnosis gout per American Rheumatism Association Criteria Classification Acute Arthritis Primary Gout . Subject take allopurinol dose least 300 mg daily least 12 week prior Day 1 , sole uratelowering therapy . Subject pregnant breastfeeding . Subject medical psychological condition , opinion Investigator and/or Medical Monitor , might create undue risk subject interfere subject 's ability comply protocol requirement ( include dual energy compute tomography imaging ) , complete study . Subject receive investigational therapy participate clinical trial research study within 30 day Day 1 . Subject take pegloticase ( KRYSTEXXAÂ® ) expect take pegloticase study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>